Aurinia Pharmaceuticals Inc.
AUPHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. With a market capitalization of $2.24B, it sits in mid-cap territory. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Market Cap
$2.24B
Beta
1.61
P/E (TTM)
7.39
P/E (Fwd)
14.43
EPS (TTM)
$2.28
EPS (Fwd)
$1.17
ROE
66.1%
ROA
15.5%
Cash
$443.0M
Total Debt
$64.1M
Free CF
$147.8M
52W Change
37.2%
Annual Financials
Cash vs Debt
Where AUPH stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, AUPH finished 4.99% above its 150-day moving average ($15.82) and 6.75% above its 200-day moving average ($15.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AUPH overbought or oversold?
At the October 15, 2026 close, AUPH's RSI(14) was 50.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aurinia Pharmaceuticals Inc. holds $443.0M in cash against $64.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $147.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 66.1%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 15.5% further supports the picture of efficient asset utilization. Revenue has grown from $134.0M (2022) to $283.1M (2025), reflecting a 111% increase over the period.
A beta of 1.61 means AUPH is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, AUPH has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing AUPH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.